Associate Professor Mark Molloy
Mark is a biochemist with 14 years experience in proteomics, specialising in separation sciences and quantitative mass spectrometry. He has strong interests in biomedical applications, in particular molecular cancer biology, and is developing methods to quantitatively profile changes in protein phosphorylation.
Mark conducted PhD research with Prof. Keith Williams in the fledgling APAF facility, and then went on to post-doctoral research with Prof. Philip Andrews in the Dept. Biological Chemistry at the University of Michigan Medical School.
Mark was employed as a Senior Principal Scientist at Pfizer Inc, in Ann Arbor, USA leading a team to identify biomarkers of new drug entities. He returned to APAF in 2004 to direct biomedical research projects.
Mark is an NHMRC RD Wright fellow undertaking research to identify prognostic and predictive colorectal cancer biomarkers. As facility Director he oversees the operations of APAF.
Dr Xiaomin Song
Dr Xiaomin Song obtained her PhD from University of Illinois at Urbana-Champaign and majored in Analytical Chemistry. She has over 20 years’ experience in mass spectrometry applications, method development and client services. Xiaomin joined APAF in 2005 and is responsible for mass spectrometry related services and researches.
Dr Alamgir Khan
Dr Alamgir Khan obtained his PhD from Macquarie University studying biochemical interactions of nematophagous fungi and plant parasitic nematodes eliciting molecular mechanisms of infection for biocontrol. Alamgir has over 13 years of experience in proteomics, primarily in the technology development, sample preparation, two-dimensional gel based separation of proteins and bead-based immuno-detection of low abundance proteins in biological samples for biomarker discovery. Alamgir joined APAF in 2005, following 5 years of industry experience gained at Proteome Systems Ltd. Alamgir has an interest in developing methods for detection of protein based drugs for anti-doping purposes. He developed a 2-D gel based immuno-detection method for erythropoietin in urine and is currently developing a method for detection of the human growth hormone in plasma.
Mr Bernie McInerney
Bernie is a protein chemist with over 25 years experience in the biotech and proteomics fields, specialising in particular in chromatography-based techniques.Prior to joining APAF he was involved in the biotechnology industry for over 15 years at Biotech Australia where he headed the analytical services group which primarily was responsible for analysing clinical grade biopharmaceutical proteins. In his early studies he isolated and characterised several novel classes of naturally occurring bioactive compounds.
Bernie joined APAF in 2000 and in his current position as manager of the protein chemistry group provides high quality services for analysing and purifying proteins. He maintains a strong interest in developing and applying new HPLC techniques to solve proteomics problems. His expertise has been recently applied to analysing difficult samples such as physiological amino acids in plasma, high sensitivity sequencing of novel peptide toxins and quantifying casein variants in milk. He is also developing improved chromatography methods for enriching phosphopeptides.
Mr Brett Cooke
Brett has extensive experience in the IT industry across a range of businesses and in a variety of roles. Prior to joining APAF to run their Informatics unit, Brett had worked as the IT Manager for P&O Nedlloyd in New Zealand, specialising in logistics and ship planning applications.
Brett has overseen the establishment and management of the bioinformatics unit at APAF since 2004. This unit provides our clients with statistical and custom analysis of their data.